Literature DB >> 11074606

Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells.

J C Shen1, R D Klein, Q Wei, Y Guan, J H Contois, T T Wang, S Chang, S D Hursting.   

Abstract

Genistein, a naturally occurring isoflavone found chiefly in soy products, reportedly has antiprostate cancer effects, but the mechanisms underlying these effects are unknown. We studied the antiproliferative and apoptosis-inducing effects of genistein in the androgen-sensitive human prostate cancer cell line LNCaP. Viable cell number was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay; cell-cycle progression and apoptosis were evaluated by flow cytometry; apoptosis was also assessed by a histone enzyme-linked immunosorbent assay; and the expression of several cell-cycle- and apoptosis-related genes and their gene products was determined by northern blot analysis, western blot analysis, and/or assays based on polymerase chain reaction. Physiologic concentrations of genistein (< or = 20 microM) decreased LNCaP viable cell number in a dose-dependent manner, induced a G(1) cell-cycle block, decreased prostate-specific antigen mRNA expression, and increased p27(KIP1) and p21(WAF1) (mRNA and protein) but had no effect on apoptosis or the mRNA expression of the apoptosis- and cell-cycle-related markers bcl-2, bax, Rb, and proliferating cell nuclear antigen. Higher concentrations of genistein (> 20 microM) did induce apoptosis. We conclude that genistein (at physiologic concentrations) exerts potent antiproliferative effects on LNCaP cells by inducing a G(1) cell-cycle block. The antiproliferative effects of genistein may be mediated by increased levels of p27(KIP1) and p21(WAF1), which are negative cell-cycle regulators that act as cyclin-dependent kinase inhibitors and that have been recently linked with prostate carcinogenesis. These findings may provide insights into the mechanisms underlying the apparent antiprostate cancer effects of soy consumption observed in epidemiologic studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074606     DOI: 10.1002/1098-2744(200010)29:2<92::aid-mc6>3.0.co;2-q

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  26 in total

1.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

2.  Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention.

Authors:  Eric A Klein
Journal:  Rev Urol       Date:  2002

3.  Genistein-induced G2/M cell cycle arrest of human intestinal colon cancer Caco-2 cells is associated with Cyclin B1 and Chk2 down-regulation.

Authors:  Junkyu Han; Yui Kurita; Hiroko Isoda
Journal:  Cytotechnology       Date:  2013-06-21       Impact factor: 2.058

Review 4.  Perspectives on the role of isoflavones in prostate cancer.

Authors:  Aamir Ahmad; Bernhard Biersack; Yiwei Li; Bin Bao; Dejuan Kong; Shadan Ali; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  AAPS J       Date:  2013-07-04       Impact factor: 4.009

5.  ATRA and Genistein synergistically inhibit the metastatic potential of human lung adenocarcinoma cells.

Authors:  Ji Cheng; Jun Qi; Xue-Tao Li; Kun Zhou; Jing-Han Xu; Yong Zhou; Guo-Qiang Zhang; Jian-Ping Xu; Ren-Jie Zhou
Journal:  Int J Clin Exp Med       Date:  2015-03-15

6.  Genistein at maximal physiologic serum levels induces G0/G1 arrest in MCF-7 and HB4a cells, but not apoptosis.

Authors:  Marcela S Tsuboy; Juliana C Marcarini; Alecsandra O de Souza; Natália A de Paula; Daniel J Dorta; Mário S Mantovani; Lucia R Ribeiro
Journal:  J Med Food       Date:  2013-12-10       Impact factor: 2.786

7.  17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.

Authors:  Yaming Qiao; Zhi-Kai Zhang; Li-Qun Cai; Chen Tan; Julianne L Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2007-12-01       Impact factor: 4.104

8.  Design and selection of soy breads used for evaluating isoflavone bioavailability in clinical trials.

Authors:  Jennifer H Ahn-Jarvis; Kenneth M Riedl; Steven J Schwartz; Yael Vodovotz
Journal:  J Agric Food Chem       Date:  2013-03-15       Impact factor: 5.279

9.  Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.

Authors:  Srilatha Swami; Aruna V Krishnan; Jacqueline Moreno; Rumi S Bhattacharyya; Christopher Gardner; James D Brooks; Donna M Peehl; David Feldman
Journal:  Int J Cancer       Date:  2009-05-01       Impact factor: 7.396

Review 10.  [A critical assessment of phytotherapy for prostate cancer].

Authors:  F G E Perabo; E C von Löw; R Siener; J Ellinger; S C Müller; P J Bastian
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.